Signostics has announced a new distribution partnership that will see its new handheld ultrasound device, the Signos RT, exclusively promoted and distributed to Australian and New Zealand markets by world-renowned precision equipment company Thermo Fisher Scientific.
Signostics’ Chief Executive Officer Warren Ortmann says the distribution agreement with the New York Stock Exchange-listed company is great news for Signostics and will help the new Signos RT penetrate the local Australian and New Zealand healthcare markets.
“The Signos RT is attracting widespread interest from medical practitioners, healthcare professionals and veterinarians globally, with this new partnership to enable our domestic customers throughout Australia and New Zealand to see and access this exciting new technology more readily,” said Mr Ortmann.
“This is yet another big step for Signostics and builds on our growing global distribution channels throughout Europe and our recently announced FDA 510(k) clearance for the Signos RT in the lucrative American market.
“We are extremely excited to be partnering with Thermo Fisher Scientific. They have a very strong reputation, understanding and connect with the Australian and New Zealand healthcare community, and are renowned for providing a high level of service to their customers.
“Signostics is looking forward to working with Thermo Fisher Scientific and seeing the Signos RT used more and more by Australian and New Zealand clinicians to help patients at the point of care.”
Thermo Fisher Scientific General Manager – Healthcare, Jarrod Percy, is anticipating a bright future with the new partnership bringing together two industry leaders.
“We are very excited about selling this truly portable and flexible point-of-care imaging tool and incorporating it into our existing product portfolio,” said Mr Percy. “Signostics has developed a revolutionary product which we believe will have a significant impact across our domestic Australian and New Zealand markets.”
The Signos RT device features unique patented technology and an award-winning design to provide a lightweight handheld ultrasound device for high quality imaging in real time at the point-of-care for medical practitioners, healthcare professionals and veterinarians globally across a broad range of clinical settings.
The Signos RT’s launch in February this year followed the launch of the original Signos in 2009, which has been widely distributed among rural and respiratory physicians, physiotherapists, continence nurses and palliative care specialists, as well as companion animal veterinarians.
The product is helping medical practitioners visually assess a patient’s internal anatomy more efficiently than ever before, with the latest innovative technology enabling rapid production of high resolution images to assist clinicians diagnose patients and improve health at a much more affordable price.
Signostics Limited is an international medical device company with a vision to be the world leader in providing clinicians with small, fast and affordable handheld ultrasound tools for use at the point-of-care.
With its head office in Adelaide, South Australia, where it was established in 2005, and with sales operations in Palo Alto, California, Signostics launched its first generation Signos device into the veterinary market in 2009 before gaining regulatory approvals to enter the human medical device market in Australia, the United States and Europe.
The Signos RT is Signostics’ second generation portable handheld ultrasound device and builds on the cutting-edge technology and platform of the original Signos device by giving users the critical ability to view high resolution ultrasound images in real time.
Continuing research, development and commercialisation of the Signos RT device has been aided by the Australian Government through the Commercialisation Australia grant program, as well as ongoing support of private investors and venture capital funding.
ABOUT THERMO FISHER SCIENTIFIC
Thermo Fisher Scientific Inc (NYSE: TMO) is the world leader in serving science. The company’s mission is to enable customers to make the world healthier, cleaner and safer. With revenues of $13 billion, the company has approximately 39,000 employees and serves customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries.
In Australia and New Zealand, Thermo Fisher Scientific’s healthcare division includes an extensive range of diagnostic and healthcare products, consumables and equipment specifically focused to hospital, medical, dental and veterinary markets. The company complements its manufactured products with key distributed brands resulting in a reliable and trusted supply chain supporting the critical activities of its customers.
For more information about Thermo Fisher Scientific visit www.thermofisher.com.au